Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Siegel

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Patient-Reported Outcomes|June 19, 2019
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)Tito R Mendoza, Loretta A Williams, Karen N Keating, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson, Omid Hamid, David Minor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.
International Journal of Clinical Oncology|December 12, 2019
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 studyNobuaki Matsubara, Go Kimura, Hiroji Uemura, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand FrameworkEvgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion studyAlessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Patient-Reported Outcomes|June 19, 2019
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM)Tito R Mendoza, Loretta A Williams, Karen N Keating, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 2, 2011
Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trialJohn A Thompson, Omid Hamid, David Minor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaJeffrey Weber, John A Thompson, Omid Hamid, et al.
International Journal of Clinical Oncology|December 12, 2019
A randomized, double-blind, comparison of radium-223 and placebo, in combination with abiraterone acetate and prednisolone, in castration-resistant metastatic prostate cancer: subgroup analysis of Japanese patients in the ERA 223 studyNobuaki Matsubara, Go Kimura, Hiroji Uemura, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Assessing the Impact of COVID-19 on the Clinical Trial Objective and Analysis of Oncology Clinical Trials-Application of the Estimand FrameworkEvgeny Degtyarev, Kaspar Rufibach, Yue Shentu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion studyAlessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Pageof 2